CJC-1295 DAC (5mg) – Long-Acting GHRH Analog for Research Use in the United States

Core Peptide USA supplies high-quality peptide compounds intended strictly for research and laboratory use only. One of our most extensively studied products is CJC-1295 DAC (5mg), a synthetic growth hormone–releasing hormone (GHRH) analog recognized for its extended half-life and prolonged biological activity in experimental models.

Researchers throughout the United States rely on Core Peptide for dependable sourcing, transparent documentation, and consistent quality. Each vial of CJC-1295 DAC (5mg) is prepared to meet stringent research standards, supporting reproducibility and accuracy in non-clinical studies.

👉 Learn more about our manufacturing and verification practices on our Quality Assurance page.

Overview of CJC-1295 DAC (5mg)

CJC-1295 DAC is a synthetic 29–amino-acid analog of endogenous growth hormone-releasing hormone (GHRH). It represents the shortest functional GHRH fragment that has been shown in studies to stimulate growth hormone secretion from somatotroph cells in the anterior pituitary gland. Compared to native GHRH, CJC-1295 DAC contains four strategic amino acid substitutions designed to enhance stability and resistance to enzymatic degradation.

What distinguishes CJC-1295 DAC (5mg) from other GHRH analogs is the inclusion of Drug Affinity Complex (DAC) technology. The DAC component involves the attachment of a lysine derivative—N-epsilon-3-maleimidopropionamide—at the peptide’s C-terminus. Researchers suggest that this modification enables reversible binding to plasma proteins such as albumin, significantly extending the peptide’s circulating half-life.

According to published research, this combination may extend the half-life of CJC-1295 DAC to approximately 6–8 days, while maintaining strong affinity for GHRH receptors, similar to non-DAC variants.

For additional background on GHRH analogs, see:

• National Center for Biotechnology Information (NCBI)

• NIH – Endocrine System Research

(External links are provided for educational reference only.)

Mechanism of Action in Research Models

Researchers propose that CJC-1295 DAC (5mg) interacts with specific binding sites on the GHRH receptor protein located on pituitary somatotroph cells. This interaction may induce conformational changes in the receptor, initiating intracellular signaling cascades mediated by G-proteins.

Once activated, these signaling pathways are believed to stimulate the production of secondary messengers such as cyclic adenosine monophosphate (cAMP) and inositol trisphosphate (IP3). These messengers may then activate protein kinases that phosphorylate transcription regulators, potentially influencing gene expression associated with growth hormone synthesis.

Increased growth hormone secretion may subsequently stimulate hepatic growth hormone receptors, potentially activating the JAK-STAT signaling pathway and promoting transcription of insulin-like growth factor-1 (IGF-1). IGF-1 is widely studied as a key mediator of growth hormone’s anabolic and growth-related effects in tissues.

Research Findings and Observations

Clinical and preclinical studies have examined CJC-1295 DAC (5mg) for its pharmacokinetic and endocrine effects. In human research models, single and repeated exposures to CJC-1295 DAC have been associated with:

• Apparent increases in mean growth hormone secretion

• Elevations in circulating IGF-1 levels

• Prolonged hormone pulsatility compared to native GHRH

Some studies report increases in growth hormone levels ranging from 2- to 10-fold, with IGF-1 elevations persisting for up to two weeks following a single exposure. Repeated administration in research settings has shown cumulative effects, with IGF-1 levels remaining elevated above baseline for extended periods.

Animal studies involving murine models have further explored the potential impact of CJC-1295 DAC on body composition. Findings suggest that exposure may support lean mass preservation and muscle hypertrophy while not promoting fat accumulation. Additionally, increased pituitary RNA and GH mRNA expression has been observed, indicating a potential proliferation of somatotroph cells in experimental models.

Chemical Makeup

Molecular Formula:
C₁₅₂H₂₅₂N₄₄O₄₂

Molecular Weight:
3367.95 g/mol

Other Known Names:
CJC-1295 with DAC, DAC:GRF, long-acting GHRH analog, tetrasubstituted GRF 1-29 with DAC

CJC-1295 DAC (5mg) Half-Life and Stability

Native GHRH is known to have a very short half-life of approximately 7 minutes. By comparison, CJC-1295 without DAC exhibits a half-life of roughly 30 minutes due to amino acid substitutions at positions 2, 8, 15, and 27. These substitutions are thought to enhance resistance to enzymatic degradation, particularly by dipeptidyl peptidase-4.

The addition of DAC technology further extends the half-life to an estimated 6–8 days, making CJC-1295 DAC (5mg) a subject of interest for long-duration endocrine signaling studies.

Quality and Compliance at Core Peptide USA

Every vial of CJC-1295 DAC (5mg) from Core Peptide USA is manufactured and handled according to strict quality control protocols. Our commitment includes:

• High-purity raw materials

• Third-party analytical verification

• Clear labeling for research use

Explore related compounds in our Research Peptides Collection.

Shipping and Research Disclaimer

Core Peptide USA ships CJC-1295 DAC (5mg) from within the United States, ensuring fast delivery and reliable tracking for domestic research institutions. This product is not intended for human or veterinary use and is sold exclusively for laboratory and research purposes.

Please review our Terms and Conditions and Research Disclaimer before ordering.

Order CJC-1295 DAC (5mg) from Core Peptide USA

For researchers seeking a trusted U.S. source of CJC-1295 DAC (5mg), Core Peptide USA offers quality, transparency, and responsive customer support. Our dedication to responsible peptide research makes us a preferred partner for laboratories nationwide